Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study

Phillips, AN; Venter, F; Havlir, D; Pozniak, A; Kuritzkes, D; Wensing, A; Lundgren, JD; ... Calmy, A; + view all Phillips, AN; Venter, F; Havlir, D; Pozniak, A; Kuritzkes, D; Wensing, A; Lundgren, JD; De Luca, A; Pillay, D; Mellors, J; Cambiano, V; Bansi-Matharu, L; Nakagawa, F; Kalua, T; Jahn, A; Apollo, T; Mugurungi, O; Clayden, P; Gupta, RK; Barnabas, R; Revill, P; Cohn, J; Bertagnolio, S; Calmy, A; - view fewer (2018) Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study. Lancet HIV 10.1016/S2352-3018(18)30317-5 . (In press). Green open access

https://ift.tt/2LkcWhr